Adept Pharma And Bioscience Excellence Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 1.98 Cr
as on 30-07-2024
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.77 Cr
as on 30-07-2024
- Satisfied Charges ₹ 0.45 Cr
as on 30-07-2024
- Revenue 0.40%
(FY 2023)
- Profit -4.55%
(FY 2023)
- Ebitda 5.33%
(FY 2023)
- Net Worth 16.57%
(FY 2023)
- Total Assets 8.49%
(FY 2023)
About Adept Pharma And Bioscience Excellence
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.98 Cr.
The company currently has active open charges totaling ₹2.77 Cr. The company has closed loans amounting to ₹4.48 M, as per Ministry of Corporate Affairs (MCA) records.
Arikatla Reddy, Arikatla Reddy, and Pasam Reddy serve as directors at the Company.
- CIN/LLPIN
U24239TG2012PTC081436
- Company No.
081436
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Adept Pharma And Bioscience Excellence Private Limited offer?
Adept Pharma And Bioscience Excellence Private Limited offers a wide range of products and services, including Pharmaceutical Services, Pharmaceutical Testing Services, Gas Analyzers, Toxicity Analyzer, Biotechnology Services.
Who are the key members and board of directors at Adept Pharma And Bioscience Excellence?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arikatla Reddy  | Managing Director | 02-Apr-2016 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arikatla Reddy | Director | 28-Oct-2018 | Current |
| Pasam Reddy | Director | 06-Jan-2022 | Current |
Financial Performance and Corporate Structure Insights of Adept Pharma And Bioscience Excellence.
Adept Pharma And Bioscience Excellence Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.4% increase. The company also saw a slight decrease in profitability, with a 4.55% decrease in profit. The company's net worth Soared by an impressive increase of 16.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adept Pharma And Bioscience Excellence?
In 2023, Adept Pharma And Bioscience Excellence had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 06 Apr 2023 | ₹2.13 M | Open |
Others Creation Date: 30 Nov 2021 | ₹5.57 M | Open |
Hdfc Bank Limited Creation Date: 09 Jul 2021 | ₹2.00 Cr | Open |
How Many Employees Work at Adept Pharma And Bioscience Excellence?
Adept Pharma And Bioscience Excellence has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Nov 23, 2018, Adept Pharma And Bioscience Excellence has raised a total of ₹ 6.88 Cr, with the most recent deal valued at ₹ 1.4 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
